Loading...
XSTOCLS B
Market cap6mUSD
Dec 23, Last price  
3.80SEK
1D
3.26%
1Q
-26.92%
Jan 2017
-99.81%
IPO
-99.69%
Name

Clinical Laserthermia Systems AB

Chart & Performance

D1W1MN
XSTO:CLS B chart
P/E
—
P/S
9.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
84.18%
Rev. gr., 5y
35.55%
Revenues
8m
+31.99%
149,999199,997350,484349,99800003,637,457614,4481,808,0001,426,0001,332,0002,245,0006,268,0008,273,000
Net income
-80m
L+12.92%
-671,199-1,977,200-4,953,543-6,974,800-12,696,862-18,325,183-17,841,372-16,594,960-26,948,911-21,263,000-32,854,999-43,375,000-57,939,000-63,615,000-70,660,000-79,792,000
CFO
-66m
L-5.99%
-69,299-2,278,091-4,917,994-5,959,696-12,046,075-18,302,855-15,742,905-18,676,887-19,626,742-24,386,339-38,724,000-39,122,000-55,407,000-66,175,000-70,688,889-66,455,000
Earnings
Feb 21, 2025

Profile

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
URL
https://clinicallaser.se/
IPO date
Apr 16, 2009
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,273
31.99%
6,268
179.20%
2,245
68.54%
Cost of revenue
7,406
11,188
50,618
Unusual Expense (Income)
NOPBT
867
(4,920)
(48,373)
NOPBT Margin
10.49%
Operating Taxes
(576)
5,879
Tax Rate
NOPAT
867
(4,343)
(54,253)
Net income
(79,792)
12.92%
(70,660)
11.07%
(63,615)
9.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
107,372
57,044
71,277
BB yield
-115.82%
-83.50%
-30.26%
Debt
Debt current
231
30,678
174
Long-term debt
454
100
Deferred revenue
Other long-term liabilities
36,612
(100)
Net debt
(14,646)
19,972
(31,097)
Cash flow
Cash from operating activities
(66,455)
(70,689)
(66,175)
CAPEX
(2,143)
(562)
(555)
Cash from investing activities
(5,497)
(886)
(408)
Cash from financing activities
76,694
61,844
85,877
FCF
1,506
(10,237)
(59,479)
Balance
Cash
15,331
10,589
31,165
Long term investments
118
205
Excess cash
14,917
10,393
31,258
Stockholders' equity
30,175
(398,092)
(318,644)
Invested Capital
29,065
436,189
339,796
ROIC
0.37%
ROCE
1.97%
EV
Common stock shares outstanding
3,359
417
288
Price
27.60
-83.15%
163.80
-80.00%
819.00
-11.36%
Market cap
92,702
35.70%
68,314
-71.00%
235,536
15.44%
EV
75,815
86,934
203,830
EBITDA
3,575
(2,470)
(47,690)
EV/EBITDA
21.20
Interest
9,760
10,972
6,405
Interest/NOPBT
1,125.15%